Search Results
Search for "Gemfibrozil" returned 18 results
Showing 1-18 out of 18
| DrugBank ID | Name | Formula | Weight |
|---|---|---|---|
DB01241
|
Gemfibrozil | C15H22O3 | 250.3334 |
| Gemfibrozil Gemfibrozil, a fibric acid antilipemic agent similar to clofibrate, is used to treat hyperlipoproteinemia and as a second-line therapy for type IIb hypercholesterolemia. It acts to ... | |||
| DB00222
|
Glimepiride | C24H34N4O5S | 490.6160 |
| ... sulfonylurea increases the effect of cyclosporine Gemfibrozil Gemfibrozil increases the effect and toxicity of rosiglitazone/pioglitazone Glucosamine Possible hyperglycemia Ketoconazole ... | |||
| DB01132
|
Pioglitazone | C19H20N2O3S | 356.4390 |
| ... Ethinyl Estradiol Possible loss of contraceptive effect Gemfibrozil Gemfibrozil increases the effect and toxicity of rosiglitazone/pioglitazone Glucosamine Possibly hyperglycemia Ketoconazole ... | |||
| DB00636
|
Clofibrate | C12H15ClO3 | 242.6990 |
| Clofibrate Clofibrate is an antilipidemic agent similar to gemfibrozil. It acts to lower elevated serum lipids by reducing the very low-density lipoprotein fraction (S<sub>f</sub> 20-400) rich in ... | |||
| DB00175
|
Pravastatin | C23H36O7 | 424.5277 |
| ... Fenofibrate Increased risk of myopathy/rhabdomyolysis Gemfibrozil Increased risk of myopathy/rhabdomyolysis Avoid alcohol. Avoid drastic changes in dietary habit. Take without regard to meals ... | |||
| DB01095
|
Fluvastatin | C24H26FNO4 | 411.4659 |
| ... Fluconazole increases the effect and toxicity of fluvastatin Gemfibrozil Increased risk of myopathy/rhabdomyolysis Rifabutin The rifamycin decreases the effect of statin drug Rifampin The ... | |||
| DB00912
|
Repaglinide | C27H36N2O4 | 452.5857 |
| ... beta-blocker decreases the symptoms of hypoglycemia Gemfibrozil Gemfibrozil increases the effect and toxicity of repaglinide Glibenclamide Similar mode of action - questionable association ... | |||
| DB00439
|
Cerivastatin | C26H34FNO5 | 459.5503 |
| ... toxicity Fenofibrate Increased risk of myopathy/rhabdomyolysis Gemfibrozil Increased risk of myopathy/rhabdomyolysis Imatinib Imatinib increases the effect and toxicity of statin Itraconazole ... | |||
| DB00440
|
Trimethoprim | C14H18N4O3 | 290.3177 |
| ... changes in therapeutic and adverse effects of Trimethoprim if Gemfibrozil is initiated, discontinued or dose changed. Ibuprofen The strong CYP2C9 inhibitor, Ibuprofen, may decrease the ... | |||
| DB00214
|
Torasemide | C16H20N4O3S | 348.4200 |
| Gemfibrozil Gemfibrozil, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate ... | |||
| DB00697
|
Tizanidine | C9H8ClN5S | 253.7110 |
| ... inhibitor Galantamine Possible antagonism of action Gemfibrozil Gemfibrozil may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co ... | |||
| DB00227
|
Lovastatin | C24H36O5 | 404.5396 |
| ... Amprenavir can possibly increase the statin toxicity Gemfibrozil Increased risk of myopathy/rhabdomyolysis Imatinib Imatinib increases the effect and toxicity of statin Itraconazole Increased ... | |||
| DB01076
|
Atorvastatin | C33H35FN2O5 | 558.6398 |
| ... Amprenavir can possibly increase the statin toxicity Gemfibrozil Increased risk of myopathy/rhabdomyolysis Imatinib Imatinib increases the effect and toxicity of atorvastatin Indinavir ... | |||
| DB00755
|
Tretinoin | C20H28O2 | 300.4351 |
| Gemfibrozil The strong CYP2C8 inhibitor, Gemfibrozil, may decrease the metabolism and clearance of oral Tretinoin. Consider alternate therapy or monitor for changes in Tretinoin effectiveness and ... | |||
| DB00675
|
Tamoxifen | C26H29NO | 371.5146 |
| ... for changes in therapeutic/adverse effects of Tamoxifen if Gemfibrozil is initiated, discontinued or dose changed. Haloperidol Haloperidol may decrease the therapeutic effect of Tamoxifen by ... | |||
| DB01124
|
Tolbutamide | C12H18N2O3S | 270.3480 |
| Gemfibrozil Gemfibrozil, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide ... | |||
| DB00726
|
Trimipramine | C20H26N2 | 294.4338 |
| Gemfibrozil The strong CYP2C19 inhibitor, Gemfibrozil, may decrease the metabolism and clearance of Trimipramine, a CYP2C19 substrate. Consider alternate therapy or monitor for changes in ... | |||
| DB00382
|
Tacrine | C13H14N2 | 198.2637 |
| Monitor the efficacy and toxicity of Tacrine if Gemfibrozil is initiated, discontinued or if the dose is changed. Ginkgo biloba Ginkgo biloba may cause additive/toxic cholinergic effects when ... | |||
Showing 1-18 out of 18